{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:49:54Z","timestamp":1790635794786,"version":"4.1.0"},"reference-count":32,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,9,2]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) causes substantial morbidity and quality-of-life impairment. We examined demographic\/clinical characteristics of patients with HS and treatment patterns, prevalence and healthcare resource utilisation\/expenditures related to HS in the real-world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective claims data of MarketScan Commercial, Medicare Supplemental and Medicaid databases (2009\u20132014).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged \u226512 years with \u22653 non-diagnostic outpatient or inpatient claims with an HS diagnosis code and \u226512 months continuous enrolment with medical and pharmacy benefits before (preindex) and after (postindex) the earliest diagnosis of HS (index) were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 11\u2009325 Commercial\/Medicare patients (mean age 37.4 years) and 5164 Medicaid patients (mean age 28.3 years). HS was more common in Medicaid than Commercial\/Medicare patients (0.301% and 0.098%, respectively, in 2014). Cellulitis and psychiatric disorders were the most common comorbidities and oral antibiotics and narcotics were the most frequently prescribed drugs preindex, with \u226510% increase postindex in both populations. HS-related inpatient costs decreased while outpatient costs increased from preindex to postindex. Medicaid patients had several risk factors that may be associated with poor outcomes (eg, high rates of prescription pain medication use, comorbidities, drug discontinuation\/interruption\/holiday, emergency department (ED) visits and hospitalisation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Commercial\/Medicare and Medicaid HS beneficiaries experience high comorbidity burden but use different treatment modalities to manage HS. Results suggest a substantial unmet need exists among this patient population, with Medicaid patients experiencing a particularly high burden of disease and expensive healthcare resource utilisation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030579","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:15:12Z","timestamp":1569917712000},"page":"e030579","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-5865","authenticated-orcid":false,"given":"Jessica","family":"Marvel","sequence":"first","affiliation":[{"name":"Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vlahiotis","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, IBM Watson Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sainski-Nguyen","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, IBM Watson Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Willson","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, IBM Watson Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kimball","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2025120520062733000_9.9.e030579.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2015.08.009","article-title":"Diagnosing hidradenitis suppurativa","volume":"34","author":"Revuz","year":"2016","journal-title":"Dermatol Clin"},{"key":"2025120520062733000_9.9.e030579.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1014163"},{"key":"2025120520062733000_9.9.e030579.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.012"},{"issue":"5 Suppl 1","key":"2025120520062733000_9.9.e030579.4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2015.07.055","article-title":"Systemic associations of hidradenitis suppurativa","volume":"73","author":"Kohorst","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025120520062733000_9.9.e030579.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.061"},{"key":"2025120520062733000_9.9.e030579.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.027"},{"key":"2025120520062733000_9.9.e030579.7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000431037","article-title":"Hidradenitis suppurativa management in the United States: an analysis of the National ambulatory medical care survey and MarketScan Medicaid databases","volume":"1","author":"Davis","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"2025120520062733000_9.9.e030579.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.020"},{"key":"2025120520062733000_9.9.e030579.9","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu078"},{"key":"2025120520062733000_9.9.e030579.10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025120520062733000_9.9.e030579.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90321-7"},{"key":"2025120520062733000_9.9.e030579.12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","article-title":"Prevalence, risk factors, and comorbidities of hidradenitis suppurativa","volume":"34","author":"Miller","year":"2016","journal-title":"Dermatol Clin"},{"key":"2025120520062733000_9.9.e030579.13","unstructured":"Genetic and Rare Diseases Information Center . National Institutes of health. hidradenitis suppurativa. Available: https:\/\/rarediseases.info.nih.gov\/diseases\/6658\/hidradenitis-suppurativa [Accessed 20 Mar 2017]."},{"key":"2025120520062733000_9.9.e030579.14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-Based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"2025120520062733000_9.9.e030579.15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"2025120520062733000_9.9.e030579.16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2025120520062733000_9.9.e030579.17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jaad.2015.06.053","article-title":"Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa","volume":"73","author":"Khalsa","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025120520062733000_9.9.e030579.18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","article-title":"Health care utilization patterns and costs for patients with hidradenitis suppurativa","volume":"150","author":"Kirby","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2025120520062733000_9.9.e030579.19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-13-103","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis","volume":"13","author":"Smoyer-Tomic","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"2025120520062733000_9.9.e030579.20","first-page":"1385","article-title":"Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs","volume":"22","author":"Livingston","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2025120520062733000_9.9.e030579.21","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29303"},{"key":"2025120520062733000_9.9.e030579.22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11239-014-1108-z","article-title":"Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis","volume":"39","author":"Lang","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"2025120520062733000_9.9.e030579.23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.13041","article-title":"The validity of the diagnostic code for hidradenitis suppurativa in an electronic database","volume":"171","author":"Kim","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025120520062733000_9.9.e030579.24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3111\/13696998.2016.1161636","article-title":"What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis","volume":"19","author":"Jemec","year":"2016","journal-title":"J Med Econ"},{"key":"2025120520062733000_9.9.e030579.25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S095026880500484X","article-title":"Cellulitis incidence in a defined population","volume":"134","author":"Ellis Simonsen","year":"2006","journal-title":"Epidemiol Infect"},{"key":"2025120520062733000_9.9.e030579.26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12567"},{"key":"2025120520062733000_9.9.e030579.27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaad.2013.06.043","article-title":"Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States","volume":"69","author":"Sung","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025120520062733000_9.9.e030579.28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ad.2019.01.004","article-title":"Hidradenitis suppurativa: estimated prevalence, clinical features, concomitant conditions, and diagnostic delay in a university teaching hospital in Buenos Aires, Argentina","volume":"110","author":"Zimman","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"2025120520062733000_9.9.e030579.29","unstructured":"United States food and drug administration. supplement approval: bla 125057\/S-393, 2015. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2015\/125057Orig1s393ltr.pdf [Accessed 20 Mar 2017]."},{"key":"2025120520062733000_9.9.e030579.30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.220"},{"key":"2025120520062733000_9.9.e030579.31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2340\/00015555-2176","article-title":"Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis","volume":"95","author":"Vlassova","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2025120520062733000_9.9.e030579.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2007.00822.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:06:38Z","timestamp":1764993998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bmjopen-2019-030579"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030579","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}